Patient engagement & telehealth · Continuous wearable monitoring
BioIntelliSense
BioIntelliSense is a continuous health monitoring company in Golden, Colorado, whose FDA-cleared BioButton wearables and BioDashboard software capture multiparameter vital signs in hospitals and at home to support virtual care and remote patient monitoring.
Strong fit
- Hospitals scaling continuous monitoring on medical-surgical floors without adding spot-check labor
- Hospital-at-home and post-discharge RPM programs that need medical-grade wearables
- Health systems that want one clinician to watch many patients through exception-based alerts
Weak fit
- Clinics that only need occasional blood-pressure or weight checks with simple cellular devices
- Buyers who want a consumer fitness wearable instead of a medical device workflow
- Teams without a plan for device logistics, charging, and reprocessing
Bottom line
BioIntelliSense puts a small FDA-cleared wearable on patients and streams vitals into a dashboard built for exception-based nursing review. It is a fit for hospitals and hospital-at-home programs that want continuous monitoring at scale. It adds device operations work, and list pricing is not public.
Score breakdown
Weights: Outcomes 35% · Product 30% · Implementation 20% · Pricing clarity 15%.
BioIntelliSense's BioButton is a wearable that collects multiparameter vital signs and biometrics continuously. In October 2024 the FDA cleared a rechargeable multi-patient BioButton and the BioDashboard clinical intelligence system for hospital virtual care. The company describes a stack that includes BioHub Wi-Fi gateways, BioCloud analytics, and BioMobile apps, covering inpatient units and home monitoring. BioDashboard is built around exception management so one clinician can watch many patients, with the company citing low notification rates and high clinician engagement in its clearance announcement.
Typical buyers are hospitals expanding continuous monitoring beyond the ICU, and programs that send patients home with medical-grade RPM. Competitors include RPM and remote care platforms such as Cadence, Health Recovery Solutions, HealthSnap, and CoachCare, plus other wearable vendors. BioIntelliSense differentiates on a multi-patient rechargeable wearable and a dashboard aimed at inpatient scale. Pricing is not published and is sold as a monitoring platform, not as a single device SKU.
Device operations are the practical constraint: charging stations, cleaning between patients, gateway coverage, and EMR integration all matter. Revenue is not disclosed. BioIntelliSense's revenue is an estimated $15 million a year, based on its Series C financing of about $58 million in December 2025, hospital deployments, and wearable ASP economics.
The company was founded in 2019. Co-founder David Wang is CEO, and co-founder James Mault, MD, is executive chairman, per the company page.
What buyers say
What people like
"We are advancing a new standard of care by automating the capture of thousands of multiparameter measurements each day and for every general care patient throughout their inpatient stay." BioIntelliSense
"Exception-based alerts are the only way continuous monitoring works on a busy med-surg floor without drowning nurses."
What people don't like
"Someone still has to charge, clean, and track hundreds of wearables, which is real ops work."
"Without a clear EMR write-back plan, the dashboard becomes another screen nurses have to check."
Where customer reviews couldn't be found, our analysts attempted to give a voice to buyer sentiment, drawing on real information from review sites, forums and product documentation.
Based on: BioIntelliSense homepage, FDA clearance announcement, and Company leadership page.
Competitor landscape
| Vendor | Overall | Ease of implementation |
|---|---|---|
| BioIntelliSense | 7.2 | 7.0 |
| Health Recovery Solutions | 7.8 | 7.6 |
| CoachCare | 7.6 | 7.5 |
| Cadence | 7.5 | 7.0 |
| HealthSnap | 7.5 | 7.6 |
Pricing
| Item | Detail |
|---|---|
| Model | Data-as-a-service platform combining BioButton wearables, gateways, cloud analytics, and BioDashboard, sold to health systems. |
| Published price | Not published. |
| What drives cost | Patient volume, inpatient versus home use, device mix, and integration scope. |
Leadership
David WangCo-founder and CEO- James Mault, MD, FACSCo-founder and Executive Chairman
- Henry LeungChief Operating Officer
Recent news
- December 2025: BioIntelliSense raised a Series C financing of about $58 million to scale continuous monitoring, according to financing databases citing SEC Form D filings.
- October 2024: The FDA cleared the rechargeable BioButton Multi-Patient wearable and BioDashboard for continuous patient monitoring in hospital virtual care programs.
Methodology
| Weight | Factor | What it measures |
|---|---|---|
| 35% | Customer outcomes | Whether buyers get measurable operational or clinical-workflow results after go-live |
| 30% | Product | Capability depth, reliability, and fit for the job the category buys |
| 20% | Implementation | How hard it is to stand up, integrate, train, and stabilize |
| 15% | Pricing clarity | Whether a buyer can model total cost without a mystery quote |
| Label | Meaning |
|---|---|
| Highly recommend | Strong outcomes and product with manageable caveats |
| Recommend | Solid fit for the right buyer; know the tradeoffs |
| Conditional | Only with a specific use case or heavy caveats |
| Not recommended | Avoid for most buyers in this category |
Read our full methodology for how we weight scores and assign recommend labels.